Trials / Completed
CompletedNCT01208467
Prognostic Biomarkers in Patients With Endometrial Cancer
Validating The Prognostic Role of ATR Mutation in Patients With Endometrioid Endometrial Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,824 (estimated)
- Sponsor
- Gynecologic Oncology Group · Network
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
Detailed description
PRIMARY OBJECTIVES: I. To validate the clinicopathologic associations and prognostic significance of ATR mutation in endometrioid endometrial cancer cases with defective DNA mismatch repair. OUTLINE: This is a multicenter study. DNA extracted from previously collected tumor samples is analyzed to validate the clinicopathologic associations and prognostic significance of ATR mutation.
Conditions
- Endometrial Adenocarcinoma
- Recurrent Uterine Corpus Carcinoma
- Stage I Uterine Corpus Cancer
- Stage II Uterine Corpus Cancer
- Stage III Uterine Corpus Cancer
- Stage IV Uterine Corpus Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Laboratory Biomarker Analysis | Correlative studies |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2014-05-01
- First posted
- 2010-09-24
- Last updated
- 2017-08-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01208467. Inclusion in this directory is not an endorsement.